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Summary 
Survivin, a member of the inhibitor of apoptosis proteins gene family, was recently shown to be expressed by tumors 
originating from different cell lineages. There are also cumulative vidences that spontaneous immune response 
against survivin derived epitopes may occur. Here, using RT-PCR, Western-blot analysis and immunohistochem- 
istry, we show that survivin is widely expressed by gliomas, meningiomas nd schwannomas, both in vitro and 
in vivo. These data indicate that survivin may serve as an attractive target for immunotherapies designed for brain 
tumors. 
Introduction 
Apoptosis is a complex program of cellular suicide, 
and inhibition of apoptosis is considered to be an 
important mechanism involved in cancer formation 
and progression by extending the life span of cells 
and thus favoring the accumulation of transforming 
mutations [ 1]. Survivin is a member of the inhibitor-of- 
apoptosis (IAP) family that blocks apoptosis pathways 
by inhibiting effector caspase molecules [2]. Whilst 
highly expressed in fetal tissues, survivin is generally 
not detectable in normal adult tissues with the excep- 
tion of thymus and placenta [2]. In contrast, expression 
of survivin was reported in the majority of malignant 
tumors arising from the lung [3], the prostate [4], the 
skin [5], the colon [6], the pancreas [7], the breast 
[8], the stomach [9], the esophagus [10] and from 
hematopoietic cells [11]. Interestingly, expression of 
survivin was shown to be associated with an unfavor- 
able prognosis of some cancers [3,10,11], supporting 
the idea that apoptosis inhibition may contribute to 
tumor progression. 
Recent data suggest hat a significant fraction of 
human astrocytomas may also express urvivin. Using 
semi-quantitative Western-blot analysis on frozen 
tumor tissues, Chakravarti et al. [12] reported that 80% 
of glioblastoma and 39% of not grade IV astrocytoma 
samples were indeed positive for survivin expression. 
However, this approach does not clarify whether tumor 
cells themselves express urvivin and to what extent 
non tumoral cells such as endothelial cells or infil- 
trating lymphocytes might contribute to the Western 
positivity. This is an important issue to explore con- 
sidering that activated lymphocytes have recently been 
shown to express urvivin [13]. Here, we provide vi- 
dence that glioma ceils express urvivin both in vitro 
and in vivo. Furthermore, survivin expression is not 
restricted to the astrocytic lineage, since most menin- 
giomas and schwannomas re also survivin positive. 
Materials and methods 
Patients 
Peripheral blood samples and tumor biopsies were col- 
lected uring surgery from 76 patients with brain tumor 
at the Geneva University Hospital from March 1995 to 
February 2002. No prior treatment was administered 
before surgery, except in one case (Ge 133). There were 
46 males and 30 females with a mean age of 48.7 years 
(range: 13-80 years) (Table 1). 
Tumor cell lines 
Melanoma cell line A375 and K562 cell line (a human 
erythroleukemia cell line) were obtained from ATCC. 
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Table 1. Survivin mRNA expression in brain tumor patients (M: male, F: female) 
Diagnosis Number of M F Mean age (range) Expression 
cases rate (%) 
Glioblastoma 23 13 10 55.6 (18-80) 91.3 
Anaplastic astrocytoma 10 5 5 44.4 (21-61) 90.0 
Grade II astrocytoma 9 7 2 36.3 (15-58) 66.7 
Grade I astrocytoma 5 4 1 29.0 (13-49) 60.0 
Oligodendroglioma 8 8 0 42.0 (24-455) 100.0 
Meningioma 10 4 6 65.0 (46-80) 60.0 
Schwannoma 11 5 6 47.0 (19-75) 100.0 
Human astrocytoma cell lines were derived from 
tumor biopsies (7 glioblastomas and 1 anaplastic 
astrocytoma) nd maintained in culture as previously 
described [14]. 
Detection of survivin mRNA 
Total RNA from frozen tumor and epileptic brain biop- 
sies or from 10 6 cells of tumor cell lines was isolated 
using RNeasy midi kit or RNeasy mini kit respectively 
(Qiagen, Hilden, Germany) following manufacturer's 
recommendations. RNA concentration was deter- 
mined using spectrophotometry. Total RNA (1 txg) 
was reverse transcribed using Supersript II (Invitrogen, 
Groningen, The Netherlands). 10% of the comple- 
mentary cDNA was used for the PCR. PCR was done 
using Ready Mix TM PCR reaction mix (Sigma, Buchs, 
Switzerland) in a final volume of 25 ~1 containing 
1 ttM of each 5' and 3' primers (forward and reverse 
primers). The primer pair used for the detection of sur- 
vivin was: 5'CACCGCATCTCTACATrCAAG 3' (for- 
ward primer); 5'GAAGTGGTGCAGCCACTCTG3' 
(reverse primer). PCR conditions were as follows: 
1 min at 94~ of initial denaturation, followed by 30 
cycles of amplification (30 s at 94~ 30 s at 58~ 30 s 
at 72~ and a final extension step of 10 min at 72~ 
To check the quality of the cDNA, human /3-actin 
cDNA amplification was performed. PCR products 
were resolved on a 1% agarose gel and stained with 
ethidium bromide. The melanoma cell line A375 was 
used as positive control. The generated PCR products 
were verified by sequencing. 
Western blot 
Human K562 cell line, human astrocytoma cell lines, 
Flu cytotoxic T cell lymphocytes (CTLs) (directed 
against M1 peptide: 58-66) and peripheral blood 
mononuclear cells (PBMC) were used for Western-blot 
analysis. Briefly, 106 cells were lysed in a lysis buffer 
containing 25 mM Tris-HC1 pH 7.5, 75 mM NaC1, 
0.5% Nonidet P40, 0.25 % sodium deoxycholate, 0.05 
% SDS and the complete protease inhibitors et (Roche 
Diagnostics, Mannheim, Germany). The samples were 
denatured in2x SDS buffer at 95~ for 5 rain then sep- 
arated on a 10% SDS-polyacrylamide gel(SDS-PAGE) 
and transferred onto nitrocellulose membrane. Filters 
were incubated with an anti-human survivin anti- 
body (R&D Systems, Abingdon, United Kingdom) 
followed by horseradish peroxidase-conjugated anti- 
rabbit immunogloblin and developed using chemo- 
luminescence detection kit (Amersham, Uppsala, 
Sweden). 
lmmunohistochemistry 
A rabbit polyclonal IgG anti-human survivin antibody 
(R&D system) was used to detect human survivin on 
brain tumor histological sections. Normal rabbit IgG 
was used as a negative control (R&D systems). For 
immunohistochemical detection, the standard avidin- 
biotin peroxydase complex technique was carried out 
by using an LSAB Kit (Dako, Glostrup, Denmark). 
Sections (3 ktm) were deparaffinized and rehydrated, 
endogenous peroxydase was quenched with 0.6% H202 
and 0.1% sodium azide (Sigma). Antigen retrieval was 
done by pressure cooking: slides were bathed in a 
10 -2 M sodium citrate buffer for 3 min. Sections were 
then incubated overnight at 4~ with the correspond- 
ing antibody at a concentration of 2 I~g/ml after a 
pre-incubation step of 15 min in a 1/10 normal swine 
serum (Dako). Biotynilated anti-rabbit immunogloblin 
and streptavidin conjugated tohorseradish peroxydase 
were then added. Finally, 3,3'-diaminobenzidine was 
used for color development, and hemalun was used for 
counterstaining. 
Results 
Survivin expression was first investigated at the mRNA 
level using RT-PCR on 76 tumor biopsies. As illustrated 
in Figure 1A for representative examples, the expected 
t~ 
astrocytomas 
A 
-1 
+ 
m ,2 
B 
,1 
t~ 
m ,2 
C 
,2 
9 E .~, 
,.m ,,f~.,~ 
D 
73 
PCR product (427 bp) was obtained in a high propor- 
tion of biopsies from all tumor types (Table 1), includ- 
ing meningioma nd schwannoma. Survivin mRNA 
was neither detected innon-tumoral brain (Figure 1D), 
nor in the contralateral brain hemisphere of tumor- 
burdened patient (data not shown). However, this type 
of analysis could not discriminate he cell type express- 
ing survivin in vivo. Thus, we analyzed a series of 
human astrocytoma cell lines and showed that tumor 
cells express urvivin at the mRNA (Figure 1B) and 
protein (Figure 2A) level. 
Recent data by others [13] suggested that activated 
T cells might express survivin in some circumstances. 
The extent o which infiltrating lymphocytes might 
contribute to the positive signals observed in tumor 
biopsies was thus an important issue to address. Whilst 
survivin mRNA was detectable in most PBMC sam- 
ples from astrocytoma patients and healthy donors 
(Figure 1C), the protein was not detected by Western- 
blot analysis (Figure 2B). This indicates that tumor 
infiltrating lymphocytes play a minor role (if any) in 
survivin expression by ex v ivo samples. 
To confirm protein expression by tumor cells, 
immunohistochemical analysis was performed. As 
illustrated in Figure 3, we observed positively stained 
tumor cells in each specimen from all types of human 
brain tumors analyzed (glioblastoma, grade III astro- 
cytoma, schwannoma, meningioma). Interestingly, 
positive cells showed atypical nucleus and were larger 
than lymphocytes, whilst perivascular lymphocytes 
and hyperplasic endothelia were negative. The number 
of positively stained cells was highly variable, even 
among samples with the same histological diagno- 
sis. This indicates that further analyses are required 
in order to investigate for possible correlation with 
the tumor type, the histological grade and the clinical 
outcome of the patients. 
Figure 1. Analysis of survivin mRNA expression i brain tumor 
biopsies, astrocytoma cell lines and PBMC and non-tumoral brain 
tissue, mRNA expression was assessed by RT-PCR. PCR prod- 
uct (427 bp) was verified by sequencing. The melanoma cell 
line A375 and K562 were used as a positive control. (A) brain 
tumor samples. (B) tumor cell lines obtained from grade III and 
grade IV astrocytoma. (C) PBMC from astrocytoma p tients and 
PBMC, CTLs flu (directed against M1 peptide: 58-66) and iso- 
lated CD8 + T cells from an healthy donor (HD). (D) non-tumoral 
(epileptic) brain sample. Results hown here have been repeated 
three times, p indicates passage; L indicates the molecular weight 
ladder. 
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Figure 2. Survivin is expressed by astrocytoma cell lines but not 
by PBMC from astrocytoma patients and healthy individual. The 
presence of survivin protein was checked by western blotting in 
glioblastoma cell lines as illustrated for Ge258 in (A), and in 
PBMC from glioblastoma patients (Ge224) and from the flu CTLs 
of an healthy donor (B). K562 cell line was used as a positive con- 
trol. The negative control used corresponds to one glioblastoma 
cell line that was found to be RT-PCR negative. Results shown 
here have been repeated three times. 
Discussion 
We have examined the expression of survivin in a large 
series of human brain tumors. We observed moderate to 
strong mRNA and protein expression in most biopsies 
from astrocytomas, oligodendrogliomas, meningiomas 
and schwannomas (Table 1), whilst no expression was 
detectable in normal brain (Figure 1D) and [2]. The 
most relevant finding of this study is the direct demon- 
stration that tumor cells themselves express urvivin, 
as assessed by mRNA and protein analysis of several 
cell lines and by immunohistochemistry of glioma, 
meningioma nd schwannoma samples. These data 
confirm and extend the observations recently reported 
by Chakravarti et al. [12]. In their study, survivin 
positivity and high protein expression levels were sug- 
gested to be of unfavorable prognostic value. However, 
the method used (i.e. Western-blot) did not identify 
the cellular source of survivin expression, and it could 
not be excluded that glioma infiltrating lymphocytes 
could contribute to the positive Western-blot signals 
therefore distorting the prognostic factor analysis. Our 
data, by clearly identifying tumor cells as the main 
Figure 3. Survivin is expressed by tumor cells in glioblastoma, schwannoma d meningioma. Sections from glioblastoma (A and B), 
schwannoma (C) and meningioma (D)were stained the rabbit IgG anti-human survivin polyclonal antibody (B-D) or an isotype-matched 
control Ab (A). Final magnification: • 
source of  survivin expression, provide indirect support 
to their assessment suggesting that survivin may be an 
important factor to prevent glioma cell apoptosis. 
The prognosis of patients with brain tumors remains 
dismal despite huge efforts to improve surgical tech- 
niques, to use heavy particles for irradiation and to 
find new drugs. To devise new treatment strategies to 
target brain tumors is therefore a critical challenge for 
the next years. For gliomas, a major impediment to the 
success of therapy is their propensity to infiltrate nor- 
mal structures, rendering demanding the specific tar- 
geting of  malignant cells whilst sparing normal cells. 
Taking advantage of the natural migratory properties 
of immune cells and their anti-tumor activities, the 
fine manipulation of the immune system appears now 
as a promising new treatment avenue [15]. However, 
the specific targeting of tumor cells requires the char- 
acterization of the antigens that can be recognized by 
immune cells. For brain neoplasia, this research field is 
far less advanced than for melanoma. A few candidates 
have been suggested, but their real capabilities to 
elicit an immune response have rarely been explored 
[16,17]. Considering its widespread expression pat- 
tern that we and others [12] have reported, survivin 
seems to be an interesting candidate to be examined. 
Indeed, its immunogenic properties have recently been 
evidenced in patients with non-CNS tumors. First, 
antibody reactivity against survivin was shown in the 
sera from some patients with lung or colorectal can- 
cer [18]. Second, it was possible to generate in vitro 
survivin-specific CD8+ effector cells, and HLA-A2 
restricted epitopes that are naturally processed have 
been identified [19]. Third, in an elegant series of 
experiments using multimeric survivin peptide/MHC 
complexes, Anderson et al. [20] showed spontaneous 
MHC-restricted response against survivin epitopes 
both in situ and ex vivo in breast cancer, leukemia 
and melanoma patients. Finally, the same authors 
reported that survivin specific T cells isolated by mag- 
netic beads coated with multimers were able to lyse 
HLA-matched tumors originating form diverse tissue 
types [21]. 
Overall, these data indicate that the eliciting or 
reinforcement of specific immune response against 
survivin is a promising approach for immunothera- 
pies designed for brain tumors. However, the clinical 
development should be performed with caution, con- 
sidering recent results showing that survivin may also 
be expressed in activated T cells, CD34 + cells, as well 
as stem cell populations that are involved in the renewal 
process of normal human colonic mucosa [2,13,22,23]. 
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